We at Sickle Cell Anemia News have brought you coverage of the latest developments in research and advances in treatment related…
Articles by Marisa Wexler, MS
New preclinical data support the ability of the ESCAPE platform, an approach Beam Therapeutics is advancing, to more safely prepare people…
The experimental gene-editing therapy EDIT-301 appears to be working largely as expected in the first two sickle cell disease…
The Qatar Ministry of Public Health has approved Endari (L-glutamine) to treat adults and children, starting at age 5,…
A Phase 1b clinical trial testing the safety and pharmacological properties of the investigational oral medication FTX-6058 in people…
A gene editing platform developed by Cellectis called TALEN was able to restore healthy hemoglobin production in preclinical models of…
Forma Therapeutics, which is currently developing an experimental treatment for sickle cell disease (SCD) called etavopivat, is being…
The National Institutes of Health (NIH) has awarded a five-year, $7.7-million grant to support a new research project that seeks…
People with sickle cell anemia (SCA) — the most common and the most severe form of sickle cell disease…
Intravenous bisphosphonate therapy can ease bone pain in children with sickle cell disease (SCD), a new study reports. The…